GILEAD SCIENCES INC (GILD) 87.83 +2.07 (+2.41%)
87.83 +2.07 (+2.41%)
US3755581036 - Common Stock - After market: 87.83 0 (0%)
Intuit Takes Over #73 Spot From Gilead Sciences
UPDATE 1-FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's antiviral drug Paxlovid, Merck's Lagevrio and Gilead Sciences' Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people.
2 Reasons This Stock Could Outperform in 2023
It would be a continuation of this year's showing.
These 3 Stocks Are Rallying While the Rest of the Market Plunges
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.
Gilead gets European approval for use of HIV drug Biktarvy in children
Gilead Sciences (GILD) on Tuesday said the European Commission had approved an expansion for its HIV drug Biktarvy for the use in children
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.
Gilead and Arcus issue update from mid-stage trial for lung cancer therapy (NASDAQ:GILD)
Gilead Sciences (GILD) and partner Arcus Biosciences (RCUS) announced Monday the results from their Phase 2 ARC-7 study for lung cancer therapies containing anti-TIGIT and anti-PD-1...
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching.
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.
Gilead Sciences Now the Most Expensive vs. BNB This Year
Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
Britain’s agency that determines if medicines should be used in the National Health Service (NHS), has recommended stopping the use of five COVID-19 treatments, including Merck & Co's's antiviral pill for high-risk patients, citing cost-effectiveness concerns. The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's hospital-administered antiviral remdesivir are effective at treating COVID-19.
Gilead Sciences to Present at Upcoming Investor Conferences
2 Top Biotech Stocks to Buy in November
Both of these companies have potential catalysts on the way.
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Has This Hot Stock Run Out of Steam?
Shares of Gilead Sciences have been have been on a tear recently.
See Which Of The Latest 13F Filers Holds Gilead Sciences
Why Shares of Gilead Sciences Rose 27.20% in October
The company's growing oncology portfolio is driving increased revenues.
UPDATE 1-Gilead, Kite in process of pausing Twitter advertising
Gilead Sciences Inc said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company. In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now. Gilead joins a growing list of U.S. companies, including General Motors and General Mills, who have either paused or are in the process of re-evaluating advertising on the social media platform.